Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: PEG-BCT-100
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 25
- Registration Number
- NCT02899286
- Locations
- ππ°
The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors
Phase 1
Completed
- Conditions
- MelanomaProstate Adenocarcinoma
- Interventions
- Biological: PEG-BCT-100
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 23
- Registration Number
- NCT02285101
- Locations
- πΊπΈ
John Wayne Cancer Institute, Santa Monica, California, United States
πΊπΈCalifornia Cancer Associates for Research and Excellence, cCARE, San Diego, California, United States
Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer
Phase 2
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: pegylated recombinant human arginase
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 27
- Registration Number
- NCT02089763
- Locations
- ππ°
Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong, Hong Kong
Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC
Phase 2
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: PACOX
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 17
- Registration Number
- NCT02089633
- Locations
- ππ°
The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma
Phase 1
Terminated
- Conditions
- LymphomaLeukemia
- Interventions
- Drug: Recombinant human arginase 1 Peg5000
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 1
- Registration Number
- NCT01551628
- Locations
- π¨π³
Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China
Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)
Phase 1
Completed
- Conditions
- NeoplasmHepatocellular Carcinoma
- Interventions
- Biological: Pegylated Recombinant Human Arginase I
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 20
- Registration Number
- NCT01092091
- Locations
- ππ°
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong
Study of Pegylated Human Recombinant Arginase for Liver Cancer
Phase 1
Completed
- Conditions
- NeoplasmHepatocellular Carcinoma
- Interventions
- Biological: Pegylated Recombinant Human Arginase IDrug: Doxorubicin
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 15
- Registration Number
- NCT00988195
- Locations
- ππ°
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong
Β© Copyright 2025. All Rights Reserved by MedPath